# Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

> **NCT04918407** · NA · COMPLETED · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 40 (actual)

## Conditions studied

- Kidney Transplant; Complications

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT04918407
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2025-07-05
- **Final completion:** 2025-08-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04918407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04918407, "Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04918407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*